Previous Close | 6.55 |
Open | 6.55 |
Bid | 6.45 x 0 |
Ask | 6.70 x 0 |
Day's Range | 6.55 - 6.55 |
52 Week Range | 3.20 - 9.25 |
Volume | |
Avg. Volume | 0 |
Market Cap | 399.253M |
Beta (5Y Monthly) | 0.93 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.35 |
Earnings Date | Mar 06, 2023 - Mar 13, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 32.71 |
In this article we are going to estimate the intrinsic value of Sutro Biopharma, Inc. ( NASDAQ:STRO ) by estimating the...
- Results from the STRO-002 (luvelta) Phase 1 dose-expansion study demonstrate that FolRα-selected patients experienced meaningful clinical benefit, with 43.8% ORR, median DOR of 5.4 months, and median PFS of 6.6 months at the higher starting dose of 5.2mg/kg - - Meaningful clinical benefit was observed in FolRα-selected patients, defined as TPS>25%, which is potentially 80% of the advanced ovarian cancer patient population - - Safety profile is generally consistent with prior data with asymptom
If you want to know who really controls Sutro Biopharma, Inc. ( NASDAQ:STRO ), then you'll have to look at the makeup...